Business Wire

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18 ...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...
FierceBiotech

Blue Earth’s phase 3 Axumin imaging study shows promise in glioma PET scans

A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...
Business Wire

Independent Clinical Studies Published Regarding Performance of Axumin® (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen ...

− Recently published retrospective studies in Urologic Oncology and Tomography assessed the impact of Androgen Deprivation Therapy (ADT) on Axumin PET imaging – BURLINGTON, Mass. & OXFORD, ...
Medical News Today

The role of PET scans in chemotherapy and what to expect

A positron emission tomography (PET) scan is an imaging technique that uses small amounts of radioactive substances. Doctors may use PET scans in chemotherapy treatments for cancer. PET scans help ...